INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC™ RNAi technology platform …
Tag Archives: mRNA
October, 2018
August, 2018
-
16 August
BioNTech Enters Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
MAINZ, Germany & NEW YORK–(BUSINESS WIRE)–BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of …
April, 2018
-
12 April
FDA to Allow Translate Bio to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis
LEXINGTON, Mass.–(BUSINESS WIRE)–Translate Bio, a leading messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company to begin a first-in-human clinical trial of MRT5005 …
January, 2018
-
5 January
CureVac and Arcturus Collaborate to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
TÜBINGEN, Germany & BOSTON & SAN DIEGO–(BUSINESS WIRE)–CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA …
October, 2017
-
18 October
Lilly and CureVac Enter Global Collaboration to Develop mRNA Cancer Vaccines
INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer …
August, 2017
-
21 August
AstraZeneca Enters Respiratory Disease mRNA Collaboration with Ethris
MUNICH & GAITHERSBURG, Md.–(BUSINESS WIRE)–Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseases …
January, 2017
-
4 January
RaNA Therapeutics Acquires Shire’s Messenger RNA Platform
CAMBRIDGE, Mass.–(BUSINESS WIRE)–RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA, today announced the acquisition of the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire plc. In addition, Shire’s former MRT employees, the group focused on the development …
July, 2016
-
6 July
Vertex and Moderna Partner to Develop mRNA Therapeutics for Cystic Fibrosis
BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Moderna Therapeutics today announced that the two companies have entered into an exclusive research collaboration and licensing agreement aimed at the discovery and development of messenger Ribonucleic Acid (mRNA) Therapeutics™ for the treatment of cystic fibrosis (CF). The three-year collaboration …
June, 2016
-
29 June
Merck and Moderna Partner to Advance Novel Personalized Cancer Vaccines with Keytruda for Multiple Types of Cancer
KENILWORTH, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck’s established leadership in immuno-oncology with Moderna’s pioneering …
October, 2015
-
30 October
Ultragenyx and Arcturus Enter Potential $1.57 Billion RNA Collaboration
NOVATO, Calif., Oct. 29, 2015 /PRNewswire/ — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover …